Browse the evidence

In 2022, 1 in 8 people in the world were living with obesity.

Practitioners should be aware of the significant prevalence of obesity.

Obesity was recognized as a disease by the German Bundestag on July 3, 2020.

This recognition may influence treatment protocols and funding for obesity management.

There is a lack of studies comparing adverse events across different populations for glucagon-like peptide-1 receptor agonists.

Further research is needed to assess the safety of glucagon-like peptide-1 receptor agonists across diverse populations.

Further research is needed to assess the long-term safety of Tirzepatide, particularly regarding cardiovascular outcomes.

Practitioners should be aware of the need for ongoing evaluation of Tirzepatide's long-term safety profile.

Interdisciplinary collaboration and communication between anaesthetists, surgeons, general practitioners, and endocrinologists are required to further investigate and establish preoperative guidelines for safe GLP-1 agonist use.

Healthcare teams should work together to create and follow guidelines for managing patients on GLP-1 agonists in surgical settings.

62% of protein supplement users were male.

Practitioners should note the gender distribution in protein supplement use.

42% of protein supplement users were aged 25–34.

Targeted educational initiatives can be focused on this age group.

Up to half of patients with diabetes mellitus are undiagnosed when referred for elective surgery.

Healthcare providers should consider screening for diabetes in patients scheduled for elective surgery.

More people around the world now have obesity than suffer from starvation.

This indicates a need for urgent public health interventions to address obesity.

The energy available in the food supply increased much more than population needs.

This suggests that dietary guidelines may need to be adjusted to account for excess energy availability.

Substantial investments in coordinated nutrition and agricultural research are needed to transform the food system.

This highlights the importance of policy and research in addressing obesity and food security.

Management of GLP-1RA adverse events lacks evidence-based support.

Healthcare providers should be cautious in applying management strategies for GLP-1RA adverse events due to the lack of evidence.

Rifampicin inhibits body weight gain in high-fat diet-fed mice.

Rifampicin may be considered as a potential treatment for obesity in high-fat diet contexts.

Mice receiving NN501 display a more gradual weight regain and no compensatory hyperphagic response after treatment cessation.

NN501 may help in maintaining weight loss without the rebound effects seen with other treatments.

Current clinical evidence does not demonstrate therapeutic benefit of GLP-1RAs in ALS.

Clinicians should be cautious in prescribing GLP-1RAs for ALS due to lack of evidence.

Women's adjusted odds of diagnosis were far higher than men's (95% confidence interval 1.66-1.75).

Healthcare providers should consider gender disparities in obesity diagnosis when assessing patients.

Obesity is defined as a BMI of more than 30 kg/m2 and is a prevalent chronic disease.

Healthcare practitioners should recognize obesity as a significant health challenge.

The incidence of obesity has nearly trebled since 1975.

Public health initiatives must address the rising rates of obesity.

There were no reports of pharmacotherapies for weight management in the studies reviewed.

Practitioners should be aware that pharmacotherapy options are not currently reported for this population.

Hepatotoxicity is not a widely recognized complication of tirzepatide.

Awareness of potential liver injury should be increased among healthcare providers prescribing tirzepatide.

The previous version of the guideline did not include a literature review for obesity surgery due to limited resources, and it references an existing guideline for obesity surgery.

Clinicians should be aware of the referenced guidelines for obesity surgery when making treatment decisions.

More work is needed to understand the mechanisms and full potential of antiobesity medicines in cancer.

Ongoing research is essential to fully understand the implications of antiobesity medications on cancer.

The present study did not find an association between resistance training (RT) and all-cause mortality.

Resistance training may not significantly impact overall mortality risk.

Neither meeting the guidelines nor monthly RT volume was associated with all-cause mortality in adjusted models.

Adherence to resistance training guidelines or volume does not appear to influence mortality risk.